China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc. (SXTC): 68 pipeline candidates. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
D/E 0.40 · 0% dilution
N/A
68 candidates
N/A
N/A
A transparent, data-derived signal for China SXT Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$10.5M
Cash
$18.1M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (68 candidates)
Showing 10 of 68 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
2
Total value held
$131K
| Holder | Shares | Value |
|---|---|---|
| sabby management, llc | 78,170 | $131K |
| royal bank of canada | 13 | $0 |
Frequently asked questions
How many drug candidates are in China SXT Pharmaceuticals, Inc.'s pipeline?
China SXT Pharmaceuticals, Inc. (SXTC) has 68 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is China SXT Pharmaceuticals, Inc.'s market capitalization?
China SXT Pharmaceuticals, Inc.'s market capitalization is approximately $10.5M.
Who is the CEO of China SXT Pharmaceuticals, Inc.?
Mr. Feng Zhou is the chief executive officer of China SXT Pharmaceuticals, Inc. (SXTC).
Get the full picture on China SXT Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.